MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 MSD will assume full responsibility for the further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback